Background-In randomized trials, statins reduce plasma levels of C-reactive protein (CRP) and low-density lipoprotein cholesterol (LDL-C), and the magnitude of event reduction relates to on-treatment levels of both. However, whether different mechanisms underlie statin-induced CRP and LDL-C reduction is unknown. Methods and Results-We performed a study to evaluate potential genetic determinants of CRP response using genome-wide genetic data from a total of 6766 participants of European ancestry randomly allocated to 20 mg/d of rosuvastatin or placebo in the JUPITER trial. Among 3386 rosuvastatin-allocated individuals, both CRP and LDL-C levels were reduced by 50% after 12 months of therapy (PϽ0.001 for both) and essentially uncorrelated (r 2 Ͻ0.03). No variants in the 3 genes (ABCG2, LPA, and APOE) that previously showed genome-wide association with LDL-C reduction in this cohort and none of the candidate single-nucleotide polymorphisms associated with LDL-C reduction were associated with rosuvastatin-induced CRP change after multiple testing correction. Among candidate single-nucleotide polymorphisms selected from prior genetic analyses of baseline CRP, CRP reduction was associated with rs2794520 in CRP (mean, Ϫ3.5% [SE, 2.0%] change in CRP per minor allele; Pϭ6.4ϫ10 Ϫ4 ) and with rs2847281 in PTPN2 (mean, 3.7% [SE, 1.9%] change in CRP per minor allele; Pϭ7.4ϫ10 Ϫ4 ). These associations remained significant after multiple testing correction but were not significant in a formal test of interaction. Neither variant was associated with rosuvastatin-induced LDL-C reduction or with CRP reduction among 3380 placebo-allocated JUPITER participants. Conclusions-The genetic determinants of rosuvastatin-induced CRP reduction differ from, and are largely independent of, the major pharmacogenetic determinants of rosuvastatin-induced LDL-C reduction. This supports the hypothesis that differing pathways may mediate the anti-inflammatory and lipid-lowering properties of statin therapy. (Circ Cardiovasc Genet. 2012;5:58-65.)
S tatins are highly effective agents for reducing cardiovascular events, and guidelines for statin therapy emphasize the achievement of low-density lipoprotein cholesterol (LDL-C) goals to maximize clinical benefit. However, statins have greatest efficacy in the presence of vascular inflammation 1,2 and reduce the inflammatory biomarker C-reactive protein (CRP) in a manner largely independent of LDL-C reduction. 3, 4 Furthermore, in several randomized trials, the magnitude of event reduction associated with statins has related to on-treatment levels of CRP and on-treatment levels of LDL-C. As examples, in the PROVE IT-TIMI 22, A to Z, and Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trials, the best clinical outcomes occurred among statin-treated participants who achieved LDL-C levels Ͻ70 mg/dL and CRP levels Ͻ1 mg/L. [5] [6] [7] Similarly, in the REVERSAL trial, regression of vascular disease, as diagnosed by intravascular ultrasonography, was observed only among statin-treated participants who reduced both CRP and LDL-C levels. 8 
Clinical Perspective on p 65
Despite these data and the inclusion of high-sensitivity CRP (hsCRP) monitoring in recent treatment guidelines, 9 the mechanism by which statins inhibit inflammation is uncertain. 10, 11 Although trial data indicate that Ͻ3% of the variance in statin-induced CRP reduction is attributable to statin-induced LDL-C reduction, 2, 3, 5, 7 inflammation and lipid oxidation are interrelated processes that may share common pathophysiological pathways. 12, 13 A better understanding of this issue is highly relevant for clinical care, because evidence that statin-mediated effects on inflammation are independent of statin-mediated effects on LDL-C would provide further support for trials specifically targeting inflammation as a potential method of lowering vascular risk.
One approach to addressing this issue is to ascertain whether genetic loci that affect the magnitude of statininduced LDL-C reduction also affect CRP reduction; in this regard, we have recently reported that variants in 3 genes (ABCG2, LPA, and APOE) are associated with LDL-C response to statin therapy in the JUPITER population at genome-wide significance, PϽ5ϫ10 Ϫ8 , 14 and we and others have provided evidence validating potential candidate singlenucleotide polymorphisms (SNPs) for statin-induced LDL-C reduction in 4 additional genes (PCSK9, HMGCR, LDLR, and SLCO1B1) in JUPITER 14 and other studies. [15] [16] [17] [18] An alternative approach is to perform a formal discovery program to ascertain whether there are any genetic loci that associate with statin-induced CRP reduction. In JUPITER, in which we previously conducted a genome-wide analysis of rosuvastatin-induced LDL-C reduction, both LDL-C and hsCRP were measured before and after initiation of rosuvastatin or placebo, affording us the unique opportunity to directly explore both of these complementary approaches.
Methods

Study Population
The Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER trial: NCT00239681) is a multinational, randomized, placebo-controlled evaluation of rosuvastatin (20 mg/d) conducted among men and women free of cardiovascular disease who had moderate-to-low levels of LDL-C (Ͻ130 mg/dL) and elevated levels of hsCRP (Ն2 mg/L). 7 As part of the JUPITER protocol, all trial participants underwent hsCRP and lipid measurements in a core laboratory facility at randomization and after 1 year of treatment with either placebo or rosuvastatin. As reported elsewhere, random allocation to rosuvastatin resulted in a 44% reduction in the trial primary end point of nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, coronary revascularization, or cardiovascular death (PϽ0.00001). 7 Consistent with prior evidence from other trials, 5, 6, 8 the relative risk reduction associated with statin therapy in the JUPITER trial was greatest in the group of participants who reduced LDL-C and who also reduced hsCRP. 19 
Genotyping and Imputation
For this pharmacogenetic evaluation focusing on statin-induced changes in CRP and LDL-C, we limited analysis to a total of 6766 JUPITER trial participants who (1) provided informed consent for genetic analyses; (2) provided baseline and 1-year blood samples that successfully underwent LDL-C and hsCRP evaluation; (3) were free of type 2 diabetes at baseline or follow-up; (4) were compliant with study medication, based on pill counts and the absence of self-reported nontrial statin use; and (5) were of European origin so that issues of population stratification could be minimized on an a priori basis.
A total of 1 006 348 SNPs were genotyped for each study participant using the Omni 1M Quad platform (Illumina; San Diego, CA) by the manufacturer and passed quality control standards, as previously described. 14 The genotyping rate for the final set of SNPs was Ͼ98.5%. Identity-by-state clustering using multidimensional scaling procedures in PLINK was used to verify self-reported European ancestry, as previously described. 14 Estimation of subpopulation stratification measures was performed in EIGENSTRAT. 20 Imputation to 6.8 million SNPs from pilot data of the 1000 Genomes Project was performed using MaCH v1.0. 21 All candidate SNP quality scores exceeded 0.3 (MaCH R 2 Ͼ0.3).
Analysis
The primary outcomes examined in this study were absolute change and percentage change in CRP and absolute and percentage change in LDL-C after 12 months of rosuvastatin or placebo therapy. Absolute change was derived from the difference between 12-month and baseline values; percentage change was derived from the absolute change divided by the baseline value. To decrease the influence of extreme outliers on absolute and percentage change, both measures were transformed using inverse-quantile normalization. 22 P values for association with change in CRP and LDL-C were calculated from analysis on transformed outcome measures. The magnitude of per-allele genetic effects and genotype medians was obtained from analysis of untransformed measures trimmed for extreme outliers.
Our initial analysis focused on whether genes associated with statin-induced reduction in LDL-C might also be associated with statin-induced reduction in hsCRP. In this phase of the analysis plan, we focused on 3 genes (ABCG2, LPA, and APOE) previously shown in the JUPITER trial to affect rosuvastatin-associated LDL-C reduction with a genome-wide level of statistical significance. 14 In addition, we evaluated SNPs in 3 additional genes (SLCO1B1, PCSK9, and LDLR), suggested from a literature review of prior statin studies, [15] [16] [17] [18] 23 that have also been validated for LDL-C reduction in JUPITER, as well as a fourth gene (HMGCR), which is the target for statin therapy and was previously reported to modify the LDL-Clowering effect of pravastatin. 23 The Bonferroni method was used to correct for multiple hypothesis testing within this set of 7 candidate genes; thus, we set the threshold to determine statistical significance in this phase of analysis to be 0.007 (␣ϭ0.05/7).
In the second phase of analysis, we sought to determine whether there are any common genetic variants associated with statin-induced reduction in CRP. In contrast to the situation for statin-induced LDL-C change, no prior data are informative on pharmacogenetic determinants of statin-induced CRP reduction. We, thus, first performed a full genome-wide analysis of statininduced CRP change within the JUPITER trial using 794 157 genotyped variants that had minor allele frequency Ͼ1% and Hardy-Weinberg equilibrium P values Ͼ10 Ϫ6 . In this exploratory analysis of potential genetic determinants of rosuvastatin-induced CRP reduction, a conventional threshold for genome-wide analyses of PϽ5.0ϫ10 Ϫ8 was selected to determine statistical significance. Linear regressions were performed in PLINK, and variants were coded assuming an additive mode of inheritance (number of minor alleles: 0, 1, and 2). Primary analytic models were adjusted for age, sex, body mass index (BMI), smoking status, region, and measures of sub-European stratification to gain power by reducing variance due to known clinical influences on CRP measures, to avoid finding genetic variants acting on CRP through their associations with body size or cigarette smoking, and to avoid confounding by subpopulation stratification.
Because the genome-wide approach to discovery for statininduced CRP variants is conservative and does not account for prior evidence or other pathophysiologic knowledge, we additionally evaluated whether candidate genes known from prior literature to affect circulating CRP levels might also affect rosuvastatin-induced changes in CRP. This prespecified analysis was undertaken using a list of 20 candidate genes recently presented by Dehghan et al 24 in a meta-analysis of genome-wide association studies of circulating CRP levels from 25 discovery cohorts, all free of statin use. The Bonferroni method was again used to correct for multiple hypothesis testing within this set of 20 candidate genes; as such, the threshold to determine statistical significance in this phase of analysis was 0.0025 (␣ϭ0.05/20). A formal test of interaction was performed for any candidate SNP associated with statin-induced CRP response after Bonferroni correction. A SNP-by-drug interaction term was added to the primary model for regression on untransformed measures of CRP response, trimmed for outliers. We also investigated whether any candidate SNPs might also be associated with rosuvastatin-induced change in LDL-C.
It is possible that candidate SNP analysis would overlook genetic effects on CRP lowering by alternative alleles in candidate loci. Therefore, a gene-wide analysis was also conducted to identify the most significant SNP in each candidate locus. P values for the most significant SNP were adjusted for multiple hypothesis testing among SNPs within 25 Kbp of the transcribed region of each gene by the permutation procedure in PLINK (50 000 permutations per gene region). 25 Several sensitivity analyses were performed to ensure the previously mentioned analyses were robust. First, genetic analyses were performed on untransformed phenotypes trimmed for outliers. Extreme outliers were excluded if measures exceeded a 2-sided z-statistic corresponding to 0.05/3386 (Ͼ4.13 SDs). This procedure excluded 36 (1.06%) individuals from analysis of absolute CRP change and excluded 29 (0.86%) individuals from analyses of percentage CRP change. Second, regression analyses excluding BMI and including SNP-by-BMI interaction as a covariate were performed. Third, to address the potential dependence of genetic effects of CRP response on baseline CRP levels, baseline CRP was included as a covariate in regression models for SNPs significantly associated with CRP response. Similarly, to address the potential dependence of genetic effects of CRP response on LDL-C response, LDL-C response was included as a covariate in regression models for SNPs significantly associated with CRP response. Finally, we addressed whether any SNPs with associations for rosuvastatin-induced CRP reduction were also associated with CRP change among the placeboallocated participants.
Under the null hypothesis of no association, P values from the regression are expected to follow a uniform (0,1) distribution. In addition, there is no linkage disequilibrium between the candidate SNPs, and each test can be considered independent of the others. The j-th order statistic from a uniform (0,1) distribution is expected to follow a ␤ distribution. 26 The 95% CI for the -log 10 transformed P values from quantile-quantile analysis, presented in the Figure, was derived using the ␤ function and projected onto the y axis.
All analyses were performed in PLINK or R 2.13.0.
Results
Of compliant JUPITER participants of European ancestry who consented for genetic research and who had baseline and 12-month hsCRP and LDL-C measures available for analysis, 3386 were randomly allocated to rosuvastatin, 20 mg/d, and 3380 were allocated to matching placebo. Randomization resulted in equal distributions of major cardiovascular risk factors between the placebo-and rosuvastatin-allocated arms (online-only Data Supplement  Table I ). Among the 3386 compliant trial participants allocated to rosuvastatin, there was a median 1.8-mg/L decrease in CRP and a 54-mg/dL decrease in LDL-C (PϽ0.001 for both). Although both of these changes over time represent a 50% reduction, there was minimal correlation for individual participants between the change in CRP and the change in LDL-C while receiving statin therapy; specifically, Ͻ3% of the variation in rosuvastatininduced change in CRP was predictable on the basis of rosuvastatin-induced effects on LDL-C (Spearman 2 ϭ 0.0025), a finding consistent with earlier studies. 1-5
Figure.
Quantile-quantile plot analysis of previously associated genome-wide association study (GWAS) single-nucleotide polymorphisms (SNPs) in 20 genes with known influence on circulating C-reactive protein (CRP) levels on the absolute change in CRP (A) and percentage change in CRP (B). The solid line indicates the expected distribution under the null hypothesis, a uniform (0,1) distribution; and the dashed lines, the 95% CI for the null hypothesis, derived using a ␤ distribution. 26 Table 1 presents data on rosuvastatin-induced CRP reduction for the SNPs at 3 genes (ABCG2, APOE, and LPA) previously identified in the JUPITER trial to have associations with rosuvastatin-induced LDL-C reduction at genome-wide significance. 14 Table 2 presents comparable data on rosuvastatin-induced changes in CRP for SNPs at 3 additional loci identified in prior studies and validated in JUPITER as having impact on statin-induced LDL-C reduction (PCSK9, SLCO1B1, and LDLR) and for HMGCR. None of the candidate SNPs at these genes was nominally associated with rosuvastatin-induced absolute or percentage reduction in CRP change.
Evaluation of SNPs That Affect Statin-Induced LDL-C Reduction for Potential Effects on CRP Reduction
To address the possibility that genetic effects on change due to alternative alleles might exist at these same candidate genes, a gene-wide analysis was conducted to identify the most significant SNP in each candidate gene region. Of the 7 candidate genes for statin-induced LDL-C reduction, no significant genewide associations were observed for statin-induced CRP reduction (online-only Data Supplement Table II) .
Power calculations, with a sample size of 3386 statinallocated participants and a Bonferroni-corrected threshold of ␣ϭ0.007, indicated this phase of the analysis had 80% power to detect SNPs, which explained 0.37% of the variance. For example, the minor allele frequency of rs2199936 in ABCG2 is 11%; therefore, we had 80% power to detect a per-allele shift of 0.8 mg/L or 10% for statin-induced CRP response. Thus, we had adequate power to detect the association with statin-induced CRP response if these SNPs influenced both statin-induced CRP response and LDL-C response at similar magnitudes.
Evaluation for Potential SNPs Associated With Rosuvastatin-Induced CRP Reduction
In a genome-wide analysis of pharmacogenetic determinants of rosuvastatin-induced CRP response, no locus reached genome-wide significance for association with either absolute change in CRP or percentage change in CRP in either the rosuvastatin-or placebo-allocated groups. Quantile-quantile analysis of the GWAS results did not suggest an excess of small P values that might not have reached genome-wide significance. Table 3 presents data on absolute and percentage reduction in CRP after rosuvastatin treatment for the 20 candidate gene SNPs described in the prior meta-analysis of genetic determinants of CRP level. 24 One SNP in IL6R was associated with absolute change in CRP only, 5 SNPs (in LEPR, CRP, NLRP3, HNF1A, and HNF4A) were associated with percentage change in CRP only, and 3 SNPs (in GPRC6A, PTPN2, and PSMG1) were associated with both absolute and percentage change in CRP. Quantile-quantile analysis of these 20 candidate SNPs shows more small P values than expected in both measures of CRP change (Figure) .
Two candidate SNPs retained statistical significance after Bonferroni correction: rs2794520 in CRP for percentage change in CRP and rs2847281 in PTPN2 for both absolute change and percentage change in CRP. Each additional minor allele at rs2794520 in CRP was associated with a 3.5% (SE, 2.0%; Pϭ6.4ϫ10 Ϫ4 ) mean decrease in percentage CRP change while receiving rosuvastatin, equivalent to observed medians for percentage CRP reduction of Ϫ49%, Ϫ53%, and Ϫ56% with 0, 1, or 2 minor alleles, respectively. SNP rs2847281 in PTPN2 was associated with a mean per-allele effect of 0.32 mg/L (SE, 0.15 mg/L; Pϭ9.9ϫ10 Ϫ4 ) in absolute CRP change while receiving rosuvastatin, equivalent to observed medians for absolute change in CRP of Ϫ1.95, Ϫ1.70, and Ϫ1.55 mg/L, with increasing copies of the minor allele. The same SNP in PTPN2 was also associated with percentage CRP change, with a mean allele effect of 3.6% (SE, 1.9%; Pϭ7.4ϫ10 Ϫ4 ), equivalent to observed medians for percentage CRP change of Ϫ54%, Ϫ50%, and Ϫ50%, with increasing copies of the minor allele. All associations remained significant after Bonferroni correction (PϽ2.5ϫ10 Ϫ3 ), with the inclusion of baseline CRP measures modeled continuously, in quartiles, and with the addition of a quadratic term to account for nonlinear associations. Although formal interaction analyses did not detect significant SNP-by-drug interaction terms for untransformed change in CRP-absolute change [P interaction (rs2847281)ϭ0.28] and percentage change [P interaction (rs2794520)ϭ0.36 and P interaction (rs2847281)ϭ0.44], this study was not adequately powered to detect interactions explaining Ͻ0.2% of the variance in untransformed CRP response.
To explore the possibility that these SNPs might have concordant effects on both statin-induced CRP reduction and statin-induced LDL-C reduction, all SNPs influencing statininduced CRP response at a nominal level of significance (PϽ0.05) were examined for association with statin-induced LDL-C change. As additionally shown in Table 3 , none of the candidate SNPs associated with rosuvastatin-induced CRP change was associated with either absolute or percentage rosuvastatin-induced change in LDL-C.
To examine potential genetic effects on change due to alternative alleles within candidate loci, a gene-wide analysis was performed to identify the most significant SNP in each candidate gene among the 20 candidate CRP genes. An investigation of these candidate gene regions resulted in 3 genes (PSMG1, PTPN2, and RORA) that contained variants with significant associations at a gene-wide significance level with absolute CRP change and 3 genes (CRP, LEPR, and PTPN2) with variants significantly associated with percentage CRP change at a gene-wide level (P perm Ͻ0.05) (onlineonly Data Supplement Table III ). Aside from the association of rs2027471 in CRP (which is in linkage disequilibrium with the CRP candidate SNP rs2794520 from Table 3 , r 2 ϭ0.93) with percentage change in CRP, after Bonferroni correction for 20 candidate genes examined, none of the other 19 gene-wide corrected P values remained significant.
Sensitivity Analyses
Analyses of CRP change that was untransformed but trimmed for extreme outliers, analyses excluding BMI adjustment, and analyses including an interaction term for SNP-by-BMI did not identify any additional genome-wide associations.
Adjustment for baseline CRP levels (modeled continuously and with quadratic terms to account for nonlinear associations between baseline CRP and statin-induced CRP response) attenuated the significance of the associations between CRP and PTPN2 and statin-induced CRP response, but remained significant at Bonferroni-corrected levels.
To further confirm that the effects in the CRP and PTPN2 genes on statin-induced CRP change were not mediated through statin-induced LDL-C change, the analyses of CRP change were repeated with the addition of LDL-C response as a covariate. The associations of rs2794520 in CRP with percentage CRP change (␤ϭϪ3.7%, SEϭ2.0%, Pϭ8.5ϫ10 Ϫ4 ), rs2847281 in PTPN2 with absolute change (␤ϭ0.32 mg/L, SEϭ0.15 mg/L, Pϭ2.1ϫ10 Ϫ3 ), and percentage change (␤ϭ3.4%, SEϭ1.9%, Pϭ1.8ϫ10 Ϫ3 ) in CRP were only slightly attenuated compared with models without LDL-C response. However, all associations retained significance below Bonferroni-corrected levels, indicating that the genetic influences of CRP and PTPN2 on change in CRP are independent of changes in LDL-C.
In addition, after Bonferroni adjustment, none of the SNPs identified to be associated with rosuvastatin-induced CRP reduction were significant predictors of absolute or percentage CRP change among the 3380 trial participants randomly allocated to placebo.
Discussion
Clinical trial data consistently indicate that statin-induced effects on CRP are not predictable on the basis of statininduced effects on LDL-C and that on-treatment levels of both biomarkers independently predict the magnitude of benefit obtained from statin therapy. [5] [6] [7] However, although these observations raise the hypothesis that separate antiinflammatory and lipid-lowering mechanisms may be responsible for each of these statin-induced effects, evidence addressing these issues has been sparse.
In this comprehensive evaluation of genetic determinants of statin-induced CRP response among 3386 rosuvastatinallocated participants of European ancestry from the JUPITER study, we observed that genetic loci that affected rosuvastatin-induced LDL-C reduction had no impact on rosuvastatin-induced CRP reduction. Conversely, in our discovery program, we found evidence of 2 genetic loci that may potentially affect rosuvastatin-induced CRP reduction, but we also found that these 2 loci were not associated with LDL-C reduction. We also confirm prior work 2,3,5 that Ͻ3% of the variation in statin-induced CRP reduction is predicted by statin-induced LDL-C reduction. Thus, the current pharmacogenetic analysis provides evidence supporting the hypothesis that the mechanisms of statin-induced inflammation inhibition are likely to differ from those of statin-induced LDL-C reduction.
We believe it is of major interest that the specific genes that affect rosuvastatin-induced LDL-C reduction have weak associations with rosuvastatin-induced CRP reduction, if any. Particularly striking are the lack of association for statininduced CRP reduction for polymorphisms in SLCO1B1 and minimal association for polymorphisms in ABCG2, variants within genes that affect the pharmacokinetics of rosuvastatin and that have strong genome-wide associations on statininduced LDL-C reduction in our study population. 14 We also believe these findings could have implications for the investigation of novel drug targets and for the inflammatory hypothesis of atherothrombosis. The 2 genetic loci found that may affect statin-induced CRP reduction are both intimately related to inflammation but have little, if any, known relationship to LDL-C. The CRP gene encodes for CRP itself. In this regard, we believe it of interest that the magnitude of absolute risk reduction attributable to rosuvastatin in the JUPITER trial has previously increased with increasing levels of CRP. 27 Furthermore, in the PROVE IT-TIMI 22 trial, in which, on-treatment levels of both CRP and LDL-C also predicted statin effectiveness, 5 genetic polymorphisms in the CRP gene have previously affected both the magnitude of inflammation during acute ischemia and long-term CRP levels after stable statin dosing. 28 The second gene in this study to potentially affect rosuvastatin-induced CRP reduction may be related to both immune function and inflammatory response. Specifically, PTPN2 encodes a T-cell protein tyrosine phosphatase that serves as a signaling protein and negative regulator of inflammation. Moreover, PTPN2 has been identified as a susceptibility gene for several inflammatory and autoimmune diseases, such as type 1 diabetes, 29 Crohn disease, 30, 31 and celiac disease 29 ; and downregulation of PTPN2 in cells and mouse PTPN2 knockouts can lead to upregulation of proinflammatory cytokines and general systemic inflammation. 32 Taken together, these observations suggest there may be alternative pharmacological mechanisms for statin-induced CRP reduction that do not operate through the same pathway as statin-induced LDL-C reduction.
The limitations of our study merit consideration. First, because of the enrollment criteria used in the JUPITER trial (low LDL-C and elevated hsCRP levels), regression to the mean could decrease the power to detect small genetic effects, particularly in the genome-wide analyses and interaction analyses, in which considerable statistical power is required. However, the fact that the relative response of CRP to rosuvastatin in JUPITER was comparable to the relative response of LDL-C, which was associated with SNPs at several loci with genome-wide significance, suggests that power was adequate for plausibly large effects. Furthermore, we did not see comparable effects among those allocated to placebo for any of the LDL-C-or CRP-reducing effects noted among those allocated to rosuvastatin, suggesting that regression to the mean is unlikely to explain our findings. Second, because our candidate investigations of rosuvastatinand LDL-C-associated variants and genes mainly focused on known pharmacodynamic pathways of statin and LDL-C metabolism, we cannot exclude the possibility that we may have missed variants or genes that do not operate through those mechanisms. Third, we used candidate SNPs and genes with known baseline CRP associations and, therefore, increased our likelihood of identifying genes that were associated with percentage change and not necessarily absolute change. However, for PTPN2, we observed statistically significant effects on both absolute and percentage CRP reduction. Fourth, neither SNP, identified in association with statin-induced CRP response, produced significant SNP-bydrug interaction terms when directly testing for interaction. However, we were not adequately powered (Ͻ80%) to detect interactions that explained Ͻ0.2% of the variance in analysis of untransformed CRP response. Fifth, regarding our null results from the CRP genome-wide analysis, it is possible the genetic influence is composed of small effects due to either rare variants or environmental interactions that we are underpowered to detect or that the genetic effect on statin-induced CRP response is dose dependent.
The results of our genetic analyses of statin-induced CRP response are consistent with the existence of largely independent pathways of statin-mediated LDL-C and inflammation reduction, as measured by CRP. This latter pathway may be one of several for reducing inflammation through pharmacological intervention. However, the definitive test of the inflammation reduction hypothesis in treating cardiovascular disease will come from randomized trials of agents that reduce inflammation without confounding beneficial effects on lipid reduction, hemostasis, or thrombosis, as is observed for statins. At least 2 such trials are being initiated, 1 using low-dose methotrexate and 1 using the novel interleukin 1␤ inhibitor, canakinumab. 33 The results of these ongoing efforts will test novel approaches for reducing the risk of atherothrombosis that go beyond current modalities of treatment and may lead us to alternative biological processes that decrease the burden of cardiovascular disease.
